Status:
COMPLETED
Clinical Trial of Dipyridamole in Schizophrenia
Lead Sponsor:
University of Maryland, Baltimore
Conditions:
Schizophrenia
Schizoaffective Disorder
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
This is a 6-week, randomized, double blind, parallel groups designed, olanzapine-controlled trial of oral dipyridamole in symptomatic patients with a (DSM IV) diagnosis of schizophrenia, schizoaffecti...
Detailed Description
Since the demonstrated success of chlorpromazine in treating psychosis in the1950's, the pharmacotherapy of schizophrenia has focused mainly on drugs with antidopaminergic actions. These drugs have ro...
Eligibility Criteria
Inclusion
- Subjects between ages 18-65, both males and nonpregnant females (on birth control) Diagnosis of schizophrenia, schizoaffective or schizophreniform disorder Ability to give written informed consent Total BPRS score \> 27 Psychosis subscale scores \> 7
Exclusion
- Patients with coagulative disorders, bleeding diathesis or currently on anticoagulants, and patients with major medical illnesses (including hypertension, angina, and cardiovascular diseases) or an abnormal baseline ECG.
- Patients with moderate to severe mental retardation.
- Inability to sign informed consent.
- Patients with a history of serious violence (e.g., suicide attempts, or assaultive behavior).
- Patients on clozapine treatment within the 6 weeks leading to the double-blind phase.
- Patients with a history of olanzapine non-response
- Positive Urine Toxicology Screen
Key Trial Info
Start Date :
May 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2011
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT00349973
Start Date
May 1 2001
End Date
September 1 2011
Last Update
November 4 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Maryland Psychiatric Research Center
Baltimore, Maryland, United States, 21228